Form 4: Dyne Therapeutics Director Edward Hurwitz Acquires Stock Options

Director Edward Hurwitz acquired stock options for 25,133 shares of Dyne Therapeutics, Inc. on May 22, 2024.

Summary

• On May 22, 2024, Edward Hurwitz, a director of Dyne Therapeutics, Inc., was granted stock options to purchase 25,133 shares of common stock.
• The exercise price of these options is $31.53 per share.
• The options vest fully on the earlier of May 22, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service.
• The options expire on May 21, 2034.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock option grants, which is neither inherently positive nor negative.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. It is a routine part of corporate governance and provides transparency to the market regarding insider transactions.

Comparison to Industry Standards

• Stock option grants to directors are a common form of compensation in the biotechnology industry.
• The vesting schedule of one year is fairly standard.
• Comparing the size of the grant to those of directors at similar-sized biotech companies (e.g., Sarepta Therapeutics, BioMarin Pharmaceutical) would provide further context on its relative significance.

Stakeholder Impact

• The grant of stock options aligns the director's interests with those of the shareholders, as the value of the options increases if the company's stock price appreciates.

Key Dates